Ocera Therapeutics — Investor Presentation (January 2017)
25 slides from Ocera Therapeutics's investor presentation, Jan 9, 2017
Slide 1: A Liver Disease Medicines Company
A Liver Disease Medicines Company NASDAQ: OCRX J A N UA R Y 2 0 1 7
Slide 2: Forward-Looking Statements
2 Forward‐Looking Statements Certain statements in this presentation constitute “forward‐looking statements” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), and Securities Exchange Act of 1934, as amended (“Exchange Act”), including, without limitation, all state
Slide 3: Seeking to Provide Continuity of Care from Treatment to Prevention
3 Seeking to Provide Continuity of Care from Treatment to Prevention Developing Therapeutics for Liver Diseases Lead Program OCR‐002 Ammonia Scavenger for Hepatic Encephalopathy (HE) IV‐Phase 2b ACUTE Oral‐Phase 1 CHRONIC
Slide 4: Investment Highlights
4 Investment Highlights OCR‐002 for Hepatic Encephalopathy (HE): ~$1.5‐2B potential U.S. market opportunity Novel ammonia scavenger; broad IP protection & WW rights IV formulation for acute use and oral formulation for chronic use Only direct ammonia scavenger in development for HE DIFFERENT
Slide 5: Experienced Leadership and a Team with Deep Clinical and Development Experience
5 LINDA S. GRAIS, MD, JD President & Chief Executive Officer STAN BUKOFZER, MD Chief Medical Officer MICHAEL BYRNES, MBA Chief Financial Officer Experienced Leadership AND a Team with Deep Clinical and Development Experience
Slide 6: Hepatic Encephalopathy: Neurocognitive Disorder in Serious Liver Disease
6 Disorientation Impaired Motor Skills Personality Changes Stupor Coma Death 0 1 2 3 4 Hepatic Encephalopathy (HE): Neurocognitive Disorder in Serious Liver Disease Blood Stream Ammonia Gut Elevated Ammonia Levels Drive HE Note: 0 to 4 as measured by West Haven Scale
Slide 7: OCR-002 Mechanism of Action: Clears Ammonia When the Liver Cannot
7 OCR‐002 Mechanism of Action: Clears Ammonia When the Liver Cannot Ornithine Contributes to Glutamate, which combines with Ammonia to Create Glutamine Gut OCR- 002 Kidney PAGN Excretion AmmoniaGlutamate PAA Combines with Glutamine to Form Phenylacetylglutamine (PAGN) Which Is Excreted Through Kidne
Slide 8: Ammonia Lowering Reduced Risk of HE in HALT-HE Study
8 Ammonia Lowering Reduced Risk of HE in HALT‐HE Study 1 “Randomized, Double‐Blind, Controlled Study of Glycerol Phenylbutrate in Hepatic Encephalopathy” Rockey, et al. Hepatology 2014; 59:1073‐1083 2 “Fasting Ammonia (NH3) as a Predictor or Hepatic Encephalopathy (HE) Events” Vierling, et al. Journ
Slide 9: OCR-002 is the Only Direct Ammonia Scavenger in Development for HE
9 OCR‐002 is the ONLY Direct Ammonia Scavenger in Development for HE Treatment and Prevention Ammonia RIFAXIMIN Non‐Absorbed Antibiotic Kills Gut Bacteria − Only approved for maintenance, not acute treatment − Does not directly clear circulating ammonia LACTULOSE Laxative, Used for Decades + Inexpen
Slide 10: OCR-002 Designed to Treat HE
10 OCR‐002 Designed to Treat HE • IV easy to administer in acute care patients – Peripheral IV line, low infusion volume and neutral pH – Rapid onset – Demonstrated favorable safety and tolerability profile in sick population – No sodium load or electrolyte disturbances • Oral formulation for chroni
Slide 11: STOP-HE Phase 2b: OCR-002 IV for Overt HE
11 • Sample size of approximately 230 patients provides 80% power to detect the difference at study‐end that was observed at the planned interim analysis STOP‐HE Phase 2b: OCR‐002 IV for Overt HE Enrollment Complete – Data Q1 2017 *As scored by a modified version of the West Haven Scale Key Exclusio
Slide 12: STOP-HE Endpoints and Meaningful Clinical Improvement
12 • Primary Endpoint: Time to meaningful clinical improvement in HE symptoms • Secondary Endpoints: Time to complete resolution of HE symptoms, % responders, length of hospital stay • Exploratory endpoints: Ammonia interrelationships, hospital discharge destination Meaningful Clinical Improvement =
Slide 13: STOP-HE Study Powering Assumptions
13 STOP‐HE Study Powering Assumptions Initial Design Following DMC Recommendation At Interim Analysis PBO Active PBO Active Percent Response thru 5 days (120 hrs) 45% 65% ? ? Median Time to Response 5.7 days (139 hrs) 3.2 days (79 hrs) ? ? Treatment Benefit 2.5 days (60 hrs)* Observed by DMC Total P
Slide 14: OCR-002 STOP-HE vs Ravicti HALT-HE Dosing Comparison
14 STUDY RAVICTI® Phase 2 HALT‐HE OCR‐002 STOP‐HE (Enrollment Complete) Dose of Drug 6mL BID = 13.2g/day 10g/15g/20g/day (depending on liver function, dose adjustment to normalize PAA levels) Mean PAA Exposure 65‐150μg/mL1 Target: 75‐150μg/mL Clinical Results Statistically significant reductions in
Slide 15: Outlook for STOP-HE
15 Outlook for STOP‐HE Favorable Safety and Tolerability Profile PROMISING FACTORS Appropriate Dosing Level Clinically Validated Mechanism Encouraging Interim Analysis Enrollment Completed; Data Expected Q1 2017
Slide 16: Oral OCR-002 Unique Opportunity
16 Oral OCR‐002 Unique Opportunity Develop orally‐administered formulation of OCR‐002 in concert with IV formulation to provide continuity of care for HE patients GOAL OF OCR‐002 ORAL PROGRAM Phase 1 program showed favorable single‐dose PK data Phase 2a study with new optimized tablet formulat
Slide 17: Proof of Principle Achieved in Phase 1 Program
17 Proof of Principle Achieved in Phase 1 Program Phase 1: Cirrhotic Patient Study – Completed Q1 17 Single Dose Orally‐Administered OCR‐002 Findings include: Single IV Dose of OCR‐002VS • Absolute bioavailability > 95% in the fasted state • Pharmacokinetics supporting convenient dosing Extended‐Rel
Slide 18: Oral OCR-002 Phase 2a Study; Initiation H1 2017
18 Oral OCR‐002 Phase 2a Study; Initiation H1 2017 Multi‐Dose Orally‐Administered OCR‐002 Glycerol Phenylbutyrate (RAVICTI®)VS Phase 2a: Cirrhotic Patients Evaluation of: • New optimized tablet formulation of OCR‐002 • Steady state pharmacokinetics • Pharmacodynamics • OCR‐002 vs. Clinically‐validat
Slide 19: Elevated Ammonia Correlated with Other Complications of Cirrhosis
19 Ammonia Brain Swelling3 Portal Hypertension2 NASH4 Protein Catabolism5 Neuronal Cell Death1 Elevated Ammonia Correlated with Other Complications of Cirrhosis; OCR‐002 Potentially Beneficial 1 Oral Presentation; Clément et al (AASLD 2015) 2 Jalan, et al “Ammonia produces pathological changes in hu
Slide 20: Addressing a Serious Problem
20 Addressing a Serious Problem Multiple Causes of Liver Disease (U.S.) CHRONIC LIVER DISEASE 30‐35M1 LIVER CIRRHOSIS 5.5M Million2 AT RISK OF OHE ~1.5‐2M3 ~200K Patients with OHE4 1 American Liver Foundation, Clinical Gastroenterology and Hepatology, 2011;9:524‐530 Zobair et al 2 Clin Liver Dis (20
Slide 21: HE: Large and Growing Healthcare Burden
21 1 HCUP Database 2 Clinical Gastroenterology and Hepatology 2012;10:1034–1041 3 Annualized based off of actual reported revenues from Q1‐16 through Q3‐16 HE: Large and Growing Healthcare Burden Rising Hospitalizations1 (000s) • Total national charges related to HE: $7 Billion2 • HE hospitalization
Slide 22: HE: Longer Hospitalization Drives Cost
22 Long Patient Stays1 HE Patient Distribution 60% >4days >14 days 15% 5‐14 days 45% 1‐4 days 40% Faster Improvement in HE Can Reduce Length of Stay 1 Ocera market research (CMS Medicare U.S. data 2011) 2 Becker’s Review / Hospital Review / May 2015 3 HCUP Hospital Intensive Care Units 2011 • ~One t
Slide 23: Significant Commercial Opportunity for IV and Oral OCR-002
23 • Seeks to provide continuity of care with IV • Goal is to prevent re‐ hospitalization and enable patients to remain stable at home ORAL • Up to 600K annual hospitalizations1 • Potentially favorable reimbursement • $1,300 / day for OCR‐0022 • Presumed standard of care • Protocol in most instituti
Slide 24: Valuable Commercial Estate
24 Valuable Commercial Estate BROAD PATENTS Composition of Matter to 2030 (not including Hatch‐Waxman extension) ORPHAN STATUS IN US WORLDWIDE RIGHTS
Slide 25: Summary and Near Term Milestones
25 HIGH HE Burden UNMET Medical Need ONLY Direct Ammonia Scavenger for HE PROMISING Clinical Programs ATTRACTIVE Commercial Opportunity NEAR TERM MILESTONES • STOP‐HE P2b Data • Oral P2a Multi‐dose Study Initiation V11022016
Ocera Therapeutics — Investor Presentation (January 2017) on 6ix